Unjha Formulations (BSE 531762)₹28.25+2.54%Pharmaceuticals
In the Jun 2026 quarter (standalone), Unjha Formulations reported sales of ₹3.32 Cr, down 8.8% from Jun 2025, and net profit of ₹0.17 Cr, down 57.5% year on year. For the year to Mar 2026, sales were ₹15.64 Cr and net profit ₹0.71 Cr.
Company filings, standalone accounts; latest reported quarter Jun 2026
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 4.77 | 5.57 | 4.44 | 3.97 | 3.79 | 3.77 | 2.45 | 3.64 | 4.30 | 4.46 | 3.34 | 3.32 |
| Expenses | 4.88 | 5.15 | 4.38 | 3.24 | 3.90 | 3.53 | 2.71 | 3.22 | 3.51 | 4.17 | 3.79 | 3.13 |
| Operating Profit | −0.12 | 0.42 | 0.07 | 0.73 | −0.12 | 0.25 | −0.27 | 0.43 | 0.80 | 0.29 | −0.46 | 0.20 |
| OPM % | −2.3% | 7.4% | 1.3% | 18.2% | −2.9% | 6.4% | −10.7% | 11.5% | 18.3% | 6.3% | −13.6% | 5.7% |
| Other Income | 0.02 | 0.00 | 0.02 | 0.00 | 0.03 | 0.02 | 0.00 | 0.00 | 0.07 | 0.00 | 0.00 | 0.00 |
| Interest | 0.00 | 0.00 | 0.04 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation | 0.01 | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 | 0.04 | 0.04 | 0.04 | 0.05 | 0.05 | 0.05 |
| Profit before tax | −0.13 | 0.40 | 0.00 | 0.69 | −0.12 | 0.22 | −0.30 | 0.40 | 0.81 | 0.23 | −0.50 | 0.16 |
| Tax % | 0.0% | 0.0% | — | 0.0% | 0.0% | 0.0% | 41.4% | 0.0% | 0.0% | 0.0% | 51.1% | 0.0% |
| Net Profit | −0.13 | 0.40 | −0.19 | 0.71 | −0.12 | 0.23 | −0.42 | 0.40 | 0.83 | 0.25 | −0.75 | 0.17 |
| EPS (Rs) | −0.26 | 0.86 | −0.39 | 1.55 | −0.24 | 0.48 | −0.91 | 0.86 | 1.82 | 0.53 | −1.64 | 0.35 |
| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 10.39 | 12.26 | 11.34 | 11.31 | 10.63 | 9.99 | 14.20 | 13.19 | 18.56 | 13.91 | 15.64 | 15.42 |
| Expenses | 10.01 | 11.87 | 10.97 | 10.99 | 10.35 | 9.84 | 13.86 | 12.72 | 17.94 | 13.35 | 14.65 | 14.60 |
| Operating Profit | 0.37 | 0.38 | 0.35 | 0.31 | 0.26 | 0.14 | 0.33 | 0.43 | 0.58 | 0.53 | 0.96 | 0.83 |
| OPM % | 3.5% | 3.0% | 3.0% | 2.7% | 2.4% | 1.3% | 2.3% | 3.3% | 3.1% | 3.7% | 6.1% | 5.4% |
| Other Income | 0.09 | 0.12 | 0.05 | 0.11 | 0.27 | 0.23 | 0.20 | 0.04 | 0.02 | 0.12 | 0.17 | 0.07 |
| Interest | 0.09 | 0.09 | 0.01 | 0.00 | 0.11 | 0.16 | 0.12 | 0.05 | 0.04 | 0.00 | 0.00 | 0.00 |
| Depreciation | 0.09 | 0.10 | 0.09 | 0.10 | 0.09 | 0.09 | 0.09 | 0.09 | 0.09 | 0.11 | 0.15 | 0.19 |
| Profit before tax | 0.27 | 0.30 | 0.25 | 0.31 | 0.30 | 0.11 | 0.29 | 0.34 | 0.46 | 0.53 | 0.97 | 0.70 |
| Tax % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 16.7% | 15.2% | 40.0% | 23.1% | 26.1% | — |
| Net Profit | 0.27 | 0.31 | 0.27 | 0.31 | 0.32 | 0.11 | 0.26 | 0.29 | 0.29 | 0.42 | 0.71 | 0.50 |
| EPS (Rs) | 0.57 | 0.66 | 0.57 | 0.66 | 0.68 | 0.21 | 0.55 | 0.61 | 0.61 | 0.91 | 1.55 | 1.06 |
| Dividend payout % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 4.49 | 4.49 | 4.49 | 4.49 | 4.49 | 4.49 | 4.49 | 4.49 | 4.49 | 4.49 | 4.49 | 4.49 |
| Reserves | −4.08 | −3.82 | −3.53 | −3.26 | −2.96 | −2.66 | −2.55 | −2.30 | −2.02 | −1.74 | −1.33 | −0.63 |
| Borrowings | 0.41 | 0.00 | 0.06 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Liabilities | 2.50 | 2.28 | 2.78 | 2.75 | 2.15 | 1.90 | 1.61 | 1.28 | 0.96 | 2.20 | 1.42 | 1.67 |
| Total Liabilities | 3.32 | 2.95 | 3.80 | 3.98 | 3.68 | 3.73 | 3.55 | 3.47 | 3.43 | 4.95 | 4.58 | 5.53 |
| Fixed Assets | 1.10 | 1.04 | 1.23 | 1.17 | 1.13 | 1.15 | 1.13 | 1.08 | 1.11 | 1.13 | 1.21 | 1.31 |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Assets | 2.22 | 1.91 | 2.57 | 2.81 | 2.55 | 2.58 | 2.42 | 2.39 | 2.32 | 3.82 | 3.37 | 4.22 |
| Inventories | 0.72 | 0.54 | 1.15 | 1.01 | 0.54 | 0.47 | 1.14 | 1.06 | 1.13 | 1.25 | 1.02 | 0.62 |
| Trade receivables | 0.67 | 0.80 | 0.64 | 0.77 | 1.33 | 1.14 | 0.97 | 0.69 | 1.04 | 1.60 | 1.50 | 1.34 |
| Cash & equivalents | 0.21 | 0.20 | 0.35 | 0.50 | 0.66 | 0.95 | 0.18 | 0.44 | 0.02 | 0.88 | 0.65 | 1.65 |
| Total Assets | 3.32 | 2.95 | 3.80 | 3.98 | 3.68 | 3.73 | 3.55 | 3.47 | 3.43 | 4.95 | 4.58 | 5.53 |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operating activity | −0.69 | 0.40 | 0.38 | 0.13 | −0.11 | 0.38 | −0.69 | 0.27 | −0.25 | 1.02 | −0.03 | 1.23 |
| Cash from investing activity | −0.08 | −0.03 | −0.27 | 0.05 | 0.05 | −0.11 | −0.07 | −0.03 | −0.11 | −0.12 | −0.19 | −0.24 |
| Cash from financing activity | 0.39 | −0.39 | 0.04 | −0.04 | 0.22 | 0.00 | 0.00 | 0.00 | −0.05 | −0.04 | 0.00 | 0.00 |
| Net cash flow | −0.39 | −0.02 | 0.16 | 0.16 | 0.17 | 0.30 | −0.78 | 0.26 | −0.43 | 0.87 | −0.24 | 1.01 |
| Capex | 0.10 | 0.03 | 0.29 | 0.00 | 0.00 | 0.11 | 0.07 | 0.03 | 0.11 | 0.12 | 0.19 | 0.24 |
| Free cash flow | −0.77 | 0.38 | 0.10 | 0.19 | −0.07 | 0.28 | −0.75 | 0.25 | −0.35 | 0.91 | −0.21 | 1.00 |
| CFO / OP % | −368.0% | 114.0% | 105.0% | 41.0% | −37.0% | 204.0% | −408.0% | 88.0% | −48.0% | 189.0% | 19.0% | 156.0% |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor days | 28 | 29 | 19 | 25 | 43 | 40 | 36 | 18 | 29 | 32 | 40 | 32 |
| Inventory days | 36 | 23 | 41 | 39 | 23 | 21 | 56 | 34 | 39 | 30 | 33 | 19 |
| Days payable | 122 | 94 | 98 | 106 | 88 | 83 | 77 | 40 | 32 | 48 | 37 | 40 |
| Cash conversion cycle | −58 | −42 | −37 | −41 | −20 | −21 | 15 | 13 | 37 | 14 | 36 | 12 |
| Working capital days | −46 | −27 | −23 | −21 | −7 | −8 | 24 | 18 | 38 | 16 | 35 | 22 |
| ROCE % | 37.6% | 49.9% | 47.5% | 25.4% | 22.7% | 25.9% | 14.4% | 21.0% | 16.8% | 19.2% | 18.0% | 27.7% |
For the Jun 2026 quarter, Unjha Formulations reported sales of ₹3.32 Cr, down 8.8% year on year and net profit of ₹0.17 Cr, down 57.5% year on year. The operating margin was 5.7%.
Unjha Formulations' sales for the year to Mar 2026 were ₹15.64 Cr; over the last twelve months they were ₹15.42 Cr.
Net profit for the year to Mar 2026 was ₹0.71 Cr, and ₹0.50 Cr over the last twelve months. Earnings per share over the same trailing period were ₹1.06.
Unjha Formulations reported borrowings of ₹0 Cr at Mar 2026, against cash and equivalents of ₹1.65 Cr.
Cash from operations was ₹1.23 Cr in the year to Mar 2026; after capital spending, free cash flow was ₹1 Cr.